VOO and VXUS both offer broad market exposure, but their ten-year return gap tells a story that challenges the standard case ...

Have you heard the news about some of the largest IPOs in history, such as SpaceX and Anthropic?Behind the glamorous ...

PFF's headline yield draws retirees chasing income, but the fund sponsor's own performance table tells a different story ...

BlackRock Capital Allocation Term Trust (NYSE: BCAT) (the "Fund") today announced the successful completion of its transferable rights offer (the "Offer") which expired on October 21, 2026 (the ...

Braveheart Bio (BRVE) looks undervalued in late-stage HCM with funded Phase 3 trials, strong cash runway and nHCM upside.

One day, some time after you started NISA.You check your valuation on your smartphone as usual, and the number is ...

Minesto intends to carry out a rights issue of approximately SEK 130 million NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA ...

EnQuest (LSE:ENQ) clears conditions for its Malaysian acquisitions while managing Magnus constraints and extending its bond debt.

Against the backdrop of a rebounding share price, a notable market contrast has emerged: while the upward share price trend ...

REDL Intermediate Holdings, LLC (together with its subsidiaries, "REDLattice"), the leading operational cyber intelligence platform providing integrated technology ...

AI means “intelligence” is now directly correlated with how much money you can spend on compute. What does this mean for ...

Scribe Therapeutics is initiated with a buy rating, targeting the in-vivo gene therapy market for cardiometabolic diseases.